Autolus Therapeutics (AUTL), following recent events with Silicon Valley Bank (SIVB), announced that the company has no business relationships with Silicon Valley Bank past or present.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AUTL:
- Autolus Therapeutics announces resignation of Chief Financial Officer
- Autolus Therapeutics price target lowered to $12 from $18 at Mizuho
- Autolus Therapeutics reports FY22 EPS ($1.57), consensus ($1.58)
- Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress
- Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023